Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患型肝炎的高危人。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在肝感染者中,重叠感染隐匿
HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,肝
人,TH1
素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是
型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究示,慢性丙肝
人,TH1细胞活素
著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素的疗。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
结果显示,慢性丙肝
人,TH1细胞活素表达显
肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活
表达显著
与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛抵抗和糖尿
是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
肝硬化的慢性丙肝(CHC)患者接受α干扰
包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的患
型肝炎的高危
。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
肝感染者中,重叠感染隐匿
HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,肝
,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的肝(CHC)患者接受α干扰素包括派罗欣治疗时存
肝功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过
工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活
表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛抵抗和糖尿
是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰包括派罗欣治疗时存在肝功能失代偿和死亡风
。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵和糖尿
是慢性丙型肝炎(CHC)中纤维化进展以
治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在肝感染者中,重叠感染隐匿
HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,肝
人,TH1
素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是
型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品人是患丙型
炎
高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙感染者中,重叠感染隐匿性HBV会影响干扰
效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙人,TH1细胞活
表达显著并与
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛抵抗和糖尿
是慢性丙型
炎(CHC)中纤维化进展以及对抗
毒治
无应答
危险因
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化
慢性丙
(CHC)患者接受α干扰
包括派罗欣治
时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。